Study identifier:D5890L00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A comparison of the efficacy of Symbicort® Single inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 inhalation b.i.d. plus as-needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26 weeks, randomised, open-label, parallel-group, multicentre study
asthma
Phase 3
No
Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy
All
1000
Interventional
12 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with conventional stepwise treatment according to asthma treatment guidelines in patients with persistent asthma
Location
Location
Zagreb, Croatia
Location
Split, Croatia
Location
Dubrovnik, Croatia
Location
Reykjavik, Iceland
Location
Akureyri, Iceland
Location
Daugavpils, Latvia
Location
Riga, Latvia
Location
Rigas raj, Latvia
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.